Daewoong Pharma
KRX:069620
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Daewoong Pharma
Cash from Financing Activities
Daewoong Pharma
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Daewoong Pharma
KRX:069620
|
Cash from Financing Activities
₩164.4B
|
CAGR 3-Years
120%
|
CAGR 5-Years
20%
|
CAGR 10-Years
9%
|
|
|
Yuhan Corp
KRX:000100
|
Cash from Financing Activities
₩8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-18%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash from Financing Activities
-₩156.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash from Financing Activities
-₩97.2B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash from Financing Activities
₩22.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cash from Financing Activities
-₩31.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
Daewoong Pharma
Glance View
Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.
See Also
What is Daewoong Pharma's Cash from Financing Activities?
Cash from Financing Activities
164.4B
KRW
Based on the financial report for Dec 31, 2025, Daewoong Pharma's Cash from Financing Activities amounts to 164.4B KRW.
What is Daewoong Pharma's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
9%
Over the last year, the Cash from Financing Activities growth was -18%. The average annual Cash from Financing Activities growth rates for Daewoong Pharma have been 120% over the past three years , 20% over the past five years , and 9% over the past ten years .
